The industry is continuing to develop orphan drugs because developers invest less to put the drugs through clinical trials and marketed at higher prices when launched. Developers also receive incentives in terms of market exclusivity, reduced R&D costs and regulatory.

Orphan Drugs & Rare Diseases Global Congress 2016 Americas will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, nonprofit organizations, orphan drugs developers as well as regional and local manufacturers. We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialization, policies, reimbursement, pricing and more. We look forward to having you be part of the event!